Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Role of VEGF in Perinatal Hypertension


Collapse Biography 

Collapse Overview 
Collapse abstract
Bronchopulmonary dysplasia (BPD), the chronic lung disease that follows premature birth, remains a major cause of morbidity and mortality. BPD is characterized by an arrest of vascular and alveolar growth and high risk for pulmonary hypertension (PH), yet mechanisms contributing to its pathogenesis and early strategies to prevent BPD are poorly understood. Strong epidemiologic studies have shown that the ?new BPD? largely reflects the long-lasting impact of antenatal factors on lung development partly due to vascular dysfunction, yet data from animal models that reflect the prenatal timing of lung injury to parallel these observations are limited. Our recent prospective clinical studies have shown that antenatal determinants as assessed on the first day of life and early echocardiogram findings of PH are strongly linked with the subsequent diagnosis of BPD at 36 weeks PMA. As highlighted in recent NIH workshops, studies that define mechanisms through which antenatal stress increases the risk for BPD and PH and early strategies that accurately identify at-risk preterm infants are high research priorities. We have previously shown that disruption of vascular endothelial growth factor (VEGF) signaling impairs lung vascular growth, decreases alveolarization and causes PH in experimental BPD, and that the effects of VEGF are largely mediated through increased endothelial production of ?angiocrine factors,? which mediate endothelial-epithelial interactions and are necessary for normal distal lung growth. Based on work from our prior funding period, we hypothesize that antenatal stress disrupts angiogenic signaling and impairs the production of critical angiocrine factors in the fetal lung that lead to sustained abnormalities of lung structure and PH after birth. More specifically, based on published and strong preliminary data, we seek to determine whether antenatal disruption of hypoxia- inducible factor (HIF) and insulin-like growth factor 1 (IGF-1) signaling contributes to the pathogenesis of BPD and whether enhancement of HIF and IGF-1 signaling are therapeutic strategies that would augment lung VEGF activity and have other beneficial effects for BPD prevention. We propose a series of translational studies that link in vivo models of preeclampsia and chorioamnionitis with in vitro studies using lung explants, isolated cell systems and molecular approaches to determine whether augmentation of VEGF activity and related downstream pathways through modulation of HIF or IGF-1 signaling can be targeted for developing new preventive therapies. To translate these findings to human disease, we propose to identify early changes in proteomic markers of angiogenic pathways to link antenatal stress with high risk for BPD from our clinical database. Finally, we will further apply novel imaging strategies to precisely define the impact of antenatal stress on distal lung architecture, cell-specific changes in gene expression in vivo, and endothelial-epithelial cell interactions in the distal lung. We further plan parallel studies with clinical lung tissue from fatal human BPD. Overall, these studies will yield new information regarding potential mechanisms through which disruption of angiocrine signaling due to adverse antenatal events alter fetal lung growth, leading to persistent abnormalities of lung structure and function. By integrating preclinical and clinical studies, we seek to provide insights into disease mechanisms and biomarkers related to angiocrine signaling that will enable the early identification of preterm newborns at risk for BPD and the development of novel preventive strategies.
Collapse sponsor award id
R01HL068702

Collapse Time 
Collapse start date
2001-06-20
Collapse end date
2022-06-30

Copyright © 2022 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)